Researcher Next
Create account
← Back to directory

Mariano Provencio

Researcher Next ID · RN-035197

Researcher · Medicine

Hospital Universitario Puerta de Hierro Majadahonda

Madrid, Spain

Sign in to saveSign in to claim
Accepting doctoral researchersFunding unknown
Works count
979
Citation count
28,734
H-index
72
i10-index
313

Research interests

Medicine
Lung Cancer Treatments and Mutations
Lung Cancer Diagnosis and Treatment
Lung Cancer Research Studies
Lymphoma Diagnosis and Treatment
Cancer Immunotherapy and Biomarkers

Publications

  • Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer

    New England Journal of Medicine · 2025 · https://doi.org/10.1056/nejmoa2502931

  • Perioperative Nivolumab in Resectable Lung Cancer

    New England Journal of Medicine · 2024 · https://doi.org/10.1056/nejmoa2311926

  • First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

    Journal of Thoracic Oncology · 2021 · https://doi.org/10.1016/j.jtho.2021.09.010

  • IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy

    Journal of Thoracic Oncology · 2020 · https://doi.org/10.1016/j.jtho.2020.01.005

  • Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial

    The Lancet Oncology · 2020 · https://doi.org/10.1016/s1470-2045(20)30453-8

  • Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study

    Journal of Clinical Oncology · 2019 · https://doi.org/10.1200/jco.19.00315

  • PLCG1 mutations in cutaneous T-cell lymphomas

    Blood · 2014 · https://doi.org/10.1182/blood-2013-05-504308

  • Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

    The Lancet Oncology · 2012 · 10.1016/s1470-2045(11)70393-x

  • Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

    New England Journal of Medicine · 2009 · 10.1056/nejmoa0904554

  • Cisplatin Plus Gemcitabine Versus a Cisplatin-Based Triplet Versus Nonplatinum Sequential Doublets in Advanced Non–Small-Cell Lung Cancer: A Spanish Lung Cancer Group Phase III Randomized Trial

    Journal of Clinical Oncology · 2003 · https://doi.org/10.1200/jco.2003.12.038

  • Patterns of Outcome and Prognostic Factors in Primary Large-Cell Lymphoma of the Testis in a Survey by the International Extranodal Lymphoma Study Group

    Journal of Clinical Oncology · 2002 · https://doi.org/10.1200/jco.2003.11.141

Current projects

    No projects listed.